A retrospective implementation study reported a large reduction in eclampsia case fatality after introducing magnesium sulfate. The program comparison did not randomize individual patients.
The historical comparison
The report examined 1,045 patients with eclampsia or pre-eclampsia during 2008–2009. Diazepam had previously been widely used in the participating setting.
Among eclampsia patients, reported case fatality fell from 20.9% to 2.3% following the magnesium intervention. The study did not identify a statistically significant difference in treatment cost, although its conclusion described a small increase.
An implementation effect has components
A change in medication can accompany training, supply improvements, referral changes, and better recognition. A retrospective before-and-after comparison cannot fully separate those factors. The overall sample should not be mistaken for the denominator of every eclampsia-specific estimate.
The study addressed an obstetric emergency in a particular health-system context, not the comparative performance of diazepam for all seizure disorders.
Reading the evidence
Preserve the diagnosis, time period, treatment system, and outcome denominator. The paper documents an important program-associated improvement, but it cannot establish that any individual death was caused by diazepam or calculate the result of switching treatment in a different patient. Cost estimates also depend on local resources and historical prices.
Source paper
Original analysis of the supplied journal article, identified as PMC3477064.
Leave a Reply